4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $4M | $19M | -147.3% | 264.4% | -$15M | $184M | $1M |
| 2024 | $6M | -$16M | 28.6% | -242.7% | -$24M | $179M | $5M |
| 2023 | $11M | -$36M | -132.1% | -332.9% | -$34M | $126M | $7M |
| 2022 | — | $4M | — | — | -$42M | $17M | $13M |
How the market has priced NA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 3 years, Nano Labs Ltd's revenue has declined 41.1% per year, and net income grown 62.8% per year. These are computed facts, not advice.
As of FY2025, Nano Labs Ltd reported $184M of total debt against $1M of cash; operating income covered interest expense 4.2×.
In FY2025, gross margin was -147.3%, operating margin 264.4%, and net margin 501.6%.
As of Jun '26, Nano Labs Ltd traded at a price-to-earnings ratio of about 1.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.